Postprandial GlycemiaNCT06960967
Effects of Chestnuts on Postprandial Glycaemic Response
A study testing Chestnut meal in people with Postprandial Glycemia and Insulin Resistance, run by Monash University at 1 site in Australia.
Trial summary
Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Postprandial Glycemia, Insulin Resistance
- What is being tested?
- Chestnut meal
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteAustralia
- Study dates
- 6 Jun 2025to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults 18-65 years old
- Available to attend two testing sessions at the research facility
Who cannot join
- Allergy to nuts and/or gluten,
- BMI<18.5 or ≥30 kg/m2,
- Fasting glucose >5.6 mmol/L, presence of diabetes and/or taking anti-diabetic medication
- Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery,
- Smoker,
- Cardiovascular disease
- Pregnant or breastfeeding women
- Presence of implanted cardiac defibrillator
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Postprandial Effects of Chestnuts on Glycaemic Response: a Cross-over Trial in Healthy Adults
Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols.
Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.
- Conditions
- Postprandial Glycemia, Insulin Resistance
- Being tested
- Chestnut meal, Control meal
- Keywords
- chestnuts, postprandial glycemia, postprandial insulinemia, glucose tolerance
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chestnut mealOther
Participants will receive an isocaloric baked meal with chestnut flour.
Control mealOther
Participants will receive an isocaloric baked meal without chestnut flour.
| Study group | Role | What they receive |
|---|---|---|
| Control meal | Placebo comparator | Participants will receive an isocaloric baked meal without chestnut flour. Receives: Other: Control meal |
| Chestnut meal | Experimental | Participants will receive an isocaloric baked meal with chestnut flour. Receives: Other: Chestnut meal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial blood glucose incremental area under the curve (iAUC)
Difference in postprandial blood glucose iAUC
Measured: Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Postprandial plasma insulin incremental area under the curve (iAUC)
Difference in postprandial plasma insulin iAUC.
Measured: Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Secondary outcomes (3)
Postprandial glucose concentration
Difference in postprandial glucose concentration
Measured: Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Postprandial insulin concentration
Difference in postprandial insulin concentration
Measured: Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Time to peak glucose
Difference in time to peak glucose
Measured: Three hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2025
- Study start6 Jun 2025
- Primary completion18 Aug 2025
- Study completion30 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postprandial GlycemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The participants will be requested to attend 2 morning visits to the research centre to receive one of the test meals. These meals will be isocaloric with or without the addition of chestnut flour. The order in which they undertake the two test visits will be randomised.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Monash University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Barbara R. Cardoso, Monash University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06960967
- Sponsor's protocol ID
- ChestnutsProject
- Status last verified
- Mar 2026
- First submitted
- 29 Apr 2025
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postprandial Effects of Chestnuts on Glycaemic Response: a Cross-over Trial in Healthy Adults
- ClinicalTrials.gov ID
- NCT06960967
- Acronym / sponsor ID
- ChestnutsProject
- Conditions
- Postprandial Glycemia, Insulin Resistance
- Keywords
- chestnuts, postprandial glycemia, postprandial insulinemia, glucose tolerance
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Monash UniversityUniversity, hospital or other
- Study start
- 6 Jun 2025 (actual)
- Primary completion
- 18 Aug 2025 (actual)
- Study completion
- 30 Apr 2026 (estimated)
- First posted
- 7 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols.
Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- The participants will be requested to attend 2 morning visits to the research centre to receive one of the test meals. These meals will be isocaloric with or without the addition of chestnut flour. The order in which they undertake the two test visits will be randomised.
| Arm | Type | Receives |
|---|---|---|
| Control meal | Placebo comparator | Other: Control mealParticipants will receive an isocaloric baked meal without chestnut flour. |
| Chestnut meal | Experimental | Other: Chestnut mealParticipants will receive an isocaloric baked meal with chestnut flour. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adults 18-65 years old
- Available to attend two testing sessions at the research facility
Key exclusion criteria (8 listed)
- Allergy to nuts and/or gluten,
- BMI<18.5 or ≥30 kg/m2,
- Fasting glucose >5.6 mmol/L, presence of diabetes and/or taking anti-diabetic medication
- Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery,
- Smoker,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chestnut mealParticipants will receive an isocaloric baked meal with chestnut flour. | Other | Chestnut meal |
| Control mealParticipants will receive an isocaloric baked meal without chestnut flour. | Other | Control meal |
Primary outcome
Postprandial blood glucose incremental area under the curve (iAUC)
Time frame: Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Difference in postprandial blood glucose iAUC
Postprandial plasma insulin incremental area under the curve (iAUC)
Time frame: Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Difference in postprandial plasma insulin iAUC.
3 secondary outcomes
Postprandial glucose concentration
Time frame: Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Postprandial insulin concentration
Time frame: Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Time to peak glucose
Time frame: Three hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Postprandial Glycemia
Not yet recruiting
Effect of Proso Millet-Based Bread on Postprandial Glycemic Response in Adults With Type 2 Diabetes
Tip 2 Diabetes Mellitus
Recruiting
Relaxing Virtual Reality Use and Blood Glucose Response to Food (ReViR) Study
Post Prandial Blood Glucose, Feasibility Pilot Study
Not yet recruiting
Chia Seed Impact on Postprandial Glycemia and Appetite in Overweight Adults
Overweight Adults, Postprandial Glycemia
Active, not recruiting
How Fig Polyphenols Affect Blood Sugar and Insulin Levels After Eating in Adults at Risk for Diabetes
Pre Diabetic
Not yet recruiting
Glycemic Effects of Meals - Repeatability Trial With Continuous Glucose Monitoring
Glucose Response
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chestnut meal in people with Postprandial Glycemia and Insulin Resistance, run by Monash University at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial blood glucose incremental area under the curve (iAUC) (time frame: Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.